Rocket Pharmaceuticals, Inc. (RCKT)
NASDAQ: RCKT · Real-Time Price · USD
3.430
-0.060 (-1.72%)
At close: Apr 28, 2026, 4:00 PM EDT
3.509
+0.079 (2.31%)
After-hours: Apr 28, 2026, 7:59 PM EDT

Rocket Pharmaceuticals Stock Forecast

RCKT's stock price has decreased by -52.56% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 13 analysts with 12-month price forecasts for Rocket Pharmaceuticals stock have an average target of 29.73, with a low estimate of 2.50 and a high estimate of 263. The average target predicts an increase of 766.76% from the current stock price of 3.43.

Analyst Consensus: Buy
Target Low Average Median High
Price $2.50 $29.73 $9.00 $263
Change -27.11% +766.76% +162.39% +7567.6%
* Price targets were last updated on Mar 30, 2026.

Analyst Ratings

The average analyst rating for Rocket Pharmaceuticals stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating Nov '25Dec '25Jan '26Feb '26Mar '26Apr '26
Strong Buy 444444
Buy 444444
Hold 555544
Sell 111111
Strong Sell 000011
Total 141414141414

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
B of A Securities
B of A Securities
Strong Buy
Maintains
$8$9
Strong Buy Maintains $8$9 +162.39% Mar 30, 2026
Chardan Capital
Chardan Capital
Strong Buy
Maintains
$11
Strong Buy Maintains $11 +220.70% Mar 27, 2026
Goldman Sachs
Goldman Sachs
Strong Sell
Maintains
$2$3
Strong Sell Maintains $2$3 -12.54% Mar 2, 2026
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Maintains
$8$10
Buy Maintains $8$10 +191.55% Feb 27, 2026
B of A Securities
B of A Securities
Strong Buy
Maintains
$10$8
Strong Buy Maintains $10$8 +133.24% Nov 18, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
14.85M
Revenue Next Year
24.40M
from 14.85M
Increased by 64.28%
EPS This Year
-1.47
from -2.01
EPS Next Year
-1.35
from -1.47
Fiscal Year FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
-----14.85M24.40M
Revenue Growth
------64.28%
EPS
-2.67-3.26-2.92-2.73-2.01-1.47-1.35
EPS Growth
-------
Forward PE
-------
No. Analysts -----1614
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20262027202820292030203120322033
High 150.2M 136.5M
Avg 14.9M 24.4M
Low n/a n/a

Revenue Growth

Revenue Growth 20262027202820292030203120322033
High -
819.2%
Avg -
64.3%
Low - -

EPS Forecast

EPS 20262027202820292030203120322033
High -0.07 -0.84
Avg -1.47 -1.35
Low -1.79 -1.89

EPS Growth

EPS Growth 20262027202820292030203120322033
High - -
Avg - -
Low - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.